Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This translates to earnings per share of a loss of $0.04, better than prior year EPS of $0.08, an improvement of 50% before preferred stock dividends |
| I'm really proud of what we've been doing, proud of what we've achieved during the last quarter |
| So we're excited about that |
| We're going to be able to present the technology, talk about what we're doing, talk about our clinical results, so it's a global conference and a great opportunity for us |
| So we're very excited about that and about his presentation |
| It's great to have engagement |
| So it's an opportunity for us to meet people, to network and to showcase what we're doing |
| As of December 31, 2023, we have 264 patents issued, pending and in process, reflecting our continuing high rate of innovation |
| All the very best to all of you. |
| Thanks so much and all the very best to you |
| We think that those are key critical to the future success of the company |
| Attending and presenting at ATTD is a really important step for us, in building awareness and growing our network in the medical and technical communities and those people globally who suffer from the pandemic of diabetes |
| Third-party analytics performed on our IP and the IP of competitors indicate that, we are the leading holder in the world |
| Their insights will help us build upon the existing knowledge and skills of our team in each of our four core work streams |
| You'll see the results of our team's intense work and dedication as we disclose some of these achievements |
| Intellectual property will continue to be a focus for the company in 2024, and as we continue to build and reinforce what we call a defensible intellectual property moat around our technology |
| And so, we are actively and aggressively exploring that path to see if, in fact, we can generate revenue without having to go through the FDA |
| Given the significant reduction in core fixed expenses, the company believes that it has enough cash and flexibility with its operating expenses to operate until at least June 30, 2024 |
| I can't speak further to that currently, but it's something we're working on very hard |
| Selling, general and administrative expenses for Q1 '24 were $2.01 million, which was higher by $106,000 than the $1.91 million in the year ago period, an increase of 5.6% |
| This trial has been critical in enabling the R&D team to collect more data in the hyper and hypoglycemic ranges |
| But thank you for your support |
| During the year ended September 30, 2023, the company made adjustments to its fixed expenses and the impact of those adjustments has significantly reduced our core monthly burn rate |
| With respect to intellectual property, we continue to grow our portfolio |
| What we've become increasingly aware of largely through market pull is that, there's a rest of the world opportunity that represents a revenue path for us that doesn't require the FDA |
| Pulling from these findings, our product team, alongside our hardware firmware, electrical engineering, and industrial design partners continue to further miniaturize Generation 1 prototype, which we'll find form in the next iteration of our device |
| Thanks for your questions |
| This increase in data will be used to further refine and inform our algorithm development, another core work stream |
| And so we have the opportunity to meet them, to talk with them about what they are doing |
| Statement |
|---|
| For Q1 fiscal '24, Know Labs reported a net loss of $3.45 million compared to a net loss of $3.82 million in Q1 fiscal '23, a reduction in net loss of 9.8% |
| Research and development expense for Q1 fiscal '24 was $1.48 million as compared to $1.74 million in Q1 fiscal '23, a decrease of 14.7% year-over-year |
| These factors may include, without limitation, risks inherent in the development and/or commercialization of potential diagnostic products, uncertainty in the results of clinical trials or regulatory approvals, the need to obtain third-party reimbursement for patients' use of any diagnostic products the company commercializes, our need and ability to obtain future capital and maintenance of IP rights, risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies or failure to maintain any laboratory accreditation or FDA certification |
| I'm not able to go in any particular detail, but for having an NDA with one or two of you, and we could go -- we could do a deeper dive, but absent that, we are really constrained with regards to what we can say about this |
| I think the thing I'll say about this is that, it's a very competitive marketplace |
| We think we've got a leg up, but at the end of the day, we have to be ever diligent in paying attention to this |
Please consider a small donation if you think this website provides you with relevant information